Infectious Enteritis Treatment Market Size & Share 2024 to 2032

Infectious Enteritis Treatment Market Size

Infectious Enteritis Treatment Market size was valued at USD 434.8 million in 2023 and is estimated to grow at 6.3% CAGR from 2024 to 2032. The market has seen notable expansion, largely propelled by the rising incidence of infectious diseases globally. Factors such as contaminated food and water sources, as well as insufficient sanitation, play a role in the transmission of enteric pathogens.

For instance, World Health Organization (WHO) reported that each year unsafe food causes 600 million cases of foodborne diseases and 420,000 deaths globally. Therefore, the increasing prevalence of foodborne illnesses leading to gastrointestinal disorders, including enteritis, contributes to an increasing demand for treatment, thereby driving market growth.  
 

Infectious enteritis treatment refers to the medical interventions aimed at managing and alleviating symptoms associated with enteritis, an inflammation of the small intestine typically caused by infectious agents such as bacteria, viruses, or parasites. Treatment strategies may include antibiotics, antiviral drugs, fluid and electrolyte replacement therapy, dietary modifications, and supportive care to relieve symptoms and promote recovery from the infection.
 

Infectious Enteritis Treatment Market Trends

Factors such as the increasing population affected by irritable bowel syndrome (IBS) and diarrhea due to infectious enteritis, coupled with extensive research and development endeavours contribute to market expansion.
 

• For instance, a study published in the Middle East Journal of Digestive Diseases estimated an IBS incidence of 38.5 per 10,000 persons annually, with a prevalence of 10-17% in the general population. Similarly, research published in BMC Medicine indicates that 10-20% of IBS cases develop following acute gastroenteritis. This heightened prevalence surged the escalating demand for treatment options, thereby driving the market growth.
   
• Furthermore, initiatives by key market players such as product launches, mergers, acquisitions, and partnerships, are anticipated to bolster market expansion.
   

Infectious Enteritis Treatment Market Analysis

Based on drug type, the market is categorized into antibiotics, antiparasitics, anti-spasmodics, and other drug types. The antibiotics segment is anticipated to acquire the largest market share and sustain its dominance to reach USD 388.5 million by end of 2032.
 

• Antibiotic medications combating bacterial infections, effectively target various enteric infections in adults such as shigellosis, salmonellosis, typhoid fever, and cholera, and will spur the segmental growth. For instance, according to an article published by the National Library of Medicine, in April 2021, acute gastroenteritis stands as one of the most prevalent bacterial infectious diseases globally, with several infections causing significant morbidity. Thus, with the rise in bacterial enteritis cases, there is a corresponding surge in demand for antibiotics, thereby fostering the market growth.

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the infectious enteritis treatment market is classified into oral and injectable. The oral route segment is projected to hold the largest market share of 71.8% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• Oral medications play a critical role in combating the infection and managing associated symptoms. Oral antibiotics are often prescribed to target the specific bacterial strains responsible for the enteritis, aiming to eradicate the infection and alleviate symptoms such as diarrhea and abdominal discomfort.
   
• Also, antidiarrheal agents, such as loperamide or bismuth subsalicylate, may also be administered orally to alleviate diarrhea symptoms and improve patient comfort.
   
• Thus, availability of several oral medications in the market to treat infectious enteritis will spur the industry growth.
   

Based on the medication drug type, the infectious enteritis treatment market is bifurcated into branded and generics. The branded segment accounted for USD 295.9 million in 2023 and is expected to account for USD 498.6 million by 2032.
 

• The branded segment has emerged as the dominant force often backed by extensive research and development efforts, carry a reputation for efficacy and safety. Also, healthcare providers and patients tend to prefer branded treatments due to their perceived higher quality and reliability. This preference, coupled with effective marketing strategies, has propelled the branded segment to prominence in the enteritis treatment landscape.
   

Based on the distribution channel, the infectious enteritis treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest share of the market and is expected to exhibit 6.1% CAGR between 2024 – 2032 period.
 

• Hospital pharmacies play a pivotal role in dispensing medications for acute illnesses including enteritis, ensuring timely access to treatment. Also, the pharmacies often stock a wide range of medications, including antibiotics and other therapeutics for enteritis management. This comprehensive availability, combined with the expertise of hospital pharmacists, has led to the segment's prominence in the market.

U.S. dominated the North American infectious enteritis treatment market accounting for the highest market revenue of 167.9 million in 2023 and is expected to show significant growth over the analysis period.
 

• Favorable regulatory frameworks, coupled with the introduction of advanced products by market players as well as increased investments by pharmaceutical companies are expected to propel regional the regional market growth in the forecast period.
   
• Also, growing awareness about the importance of early infectious disease diagnosis and treatment, coupled with advancements in diagnostic technologies and treatment modalities, encourages individuals to seek medical care. As a result, there is a rising demand for effective treatments and therapies to manage and alleviate symptoms of infectious enteritis, thereby supplementing the market growth.
   

The Asia Pacific infectious enteritis treatment market is poised for rapid growth with a CAGR of 6.7% during the forecast period.
 

• The Asia Pacific region is poised for significant growth in the market due to factors such as rapid urbanization, increasing healthcare expenditure, and expanding access to healthcare services. Also, rising incidences of enteric infections in the region, coupled with government initiatives to improve healthcare infrastructure and promote research and development, further bolster market expansion prospects in the Asia Pacific.
   

Infectious Enteritis Treatment Market Share

The infectious enteritis treatment industry hosts numerous companies competing for market share. Key players dominate with their comprehensive treatment offerings for gastrointestinal disorders such as IBS and enteritis. These companies compete through product innovation, regulatory approvals, and strategic partnerships to capture market share and address the diverse needs of patients and healthcare providers.
 

Infectious Enteritis Treatment Market Companies

Some of the prominent players operating in the infectious enteritis treatment industry include:

• Abbott Laboratories
• Almirall SA
• AstraZeneca PLC
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd
• GSK plc
• Medimetriks Pharmaceuticals Inc.
• Merck KGaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.
   

Infectious Enteritis Treatment Industry News:

• In November 2022, GSK plc obtained FDA approval for a new oral-dosing applicator-only presentation of ROTARIX, a rotavirus vaccine, easing preparation for healthcare providers by eliminating the need for dose reconstitution. This aims to offer healthcare providers a more convenient option, thereby strengthening its business portfolio.
   
• In April 2022, Ardelyx, Inc. introduced IBSRELA, the initial and sole NHE3 inhibitor tailored for alleviating irritable bowel syndrome with constipation (IBS-C) in adults. This strategy enabled company to add value to its business portfolio.
   

The infectious enteritis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Antibiotics
• Antiparasitics
• Anti-spasmodics
• Other drug types

Market, By Route of Administration

• Oral
• Injectable

Market, By Medication Type

• Branded
• Generics

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa